Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels

(NASDAQ:TNDM) SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insul